Total Payments
$189,919
2024 Payments
$541.51
Companies
31
Transactions
358
Medicare Patients
7,777
Medicare Billing
$2.2M
Payment Breakdown by Category
Research$170,014 (89.5%)
Other$11,277 (5.9%)
Food & Beverage$4,180 (2.2%)
Consulting$2,646 (1.4%)
Travel$1,795 (0.9%)
Education$6.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $170,014 | 184 | 89.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,015 | 6 | 4.2% |
| Food and Beverage | $4,180 | 154 | 2.2% |
| Honoraria | $3,262 | 2 | 1.7% |
| Consulting Fee | $2,646 | 5 | 1.4% |
| Travel and Lodging | $1,795 | 6 | 0.9% |
| Education | $6.96 | 1 | 0.0% |
Payments by Type
Research
$170,014
184 transactions
General
$19,905
174 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADMA BioManufacturing LLC | $170,106 | 189 | $0 (2024) |
| Allergan, Inc. | $9,262 | 38 | $0 (2020) |
| The Medicines Company | $4,071 | 13 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $2,421 | 3 | $0 (2023) |
| Sanofi Pasteur Inc. | $1,248 | 5 | $0 (2018) |
| Octapharma USA, Inc. | $494.13 | 2 | $0 (2024) |
| Insmed, Inc. | $380.91 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $266.45 | 15 | $0 (2024) |
| ABBVIE INC. | $218.78 | 14 | $0 (2024) |
| Gilead Sciences, Inc. | $193.02 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $541.51 | 20 | Recor Medical Inc ($110.27) |
| 2023 | $173,279 | 210 | ADMA BioManufacturing LLC ($170,052) |
| 2022 | $221.15 | 14 | Melinta Therapeutics, LLC ($43.42) |
| 2021 | $249.23 | 16 | AbbVie Inc. ($151.31) |
| 2020 | $311.09 | 9 | Allergan, Inc. ($249.60) |
| 2019 | $3,745 | 16 | Allergan Inc. ($3,666) |
| 2018 | $3,537 | 30 | Allergan Inc. ($1,921) |
| 2017 | $8,035 | 43 | The Medicines Company ($4,071) |
All Payment Transactions
358 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $110.27 | General |
| Category: Endovascular | ||||||
| 11/06/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Respiratory | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.83 | General |
| 08/26/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Respiratory | ||||||
| 07/31/2024 | ADMA BioManufacturing LLC | — | Consulting Fee | Cash or cash equivalent | $18.66 | General |
| 07/22/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Respiratory | ||||||
| 07/22/2024 | HOSPIRA, INC. | CUTAQUIG (Biological) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.67 | General |
| 07/10/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: IMMUNOLOGY | ||||||
| 06/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Respiratory | ||||||
| 06/04/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/30/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: IMMUNOLOGY | ||||||
| 02/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.41 | General |
| 02/20/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Respiratory | ||||||
| 01/31/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $108.38 | General |
| Category: Inflammation | ||||||
| 01/30/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ANTIFUNGALS | ||||||
| 12/11/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Respiratory | ||||||
| 11/30/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/08/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Respiratory | ||||||
| 09/18/2023 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $477.47 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,432 | 50,300 | $1.1M | $464,547 |
| 2022 | 17 | 1,583 | 44,120 | $938,580 | $394,086 |
| 2021 | 17 | 2,144 | 69,677 | $1.6M | $665,675 |
| 2020 | 21 | 2,618 | 71,406 | $1.7M | $723,362 |
Total Patients
7,777
Total Services
235,503
Medicare Billing
$2.2M
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 37 | 3,590 | $520,550 | $203,080 | 39.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 360 | 1,824 | $218,880 | $107,141 | 48.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 193 | 699 | $122,325 | $61,833 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 266 | 296 | $95,350 | $37,972 | 39.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 114 | 247 | $34,580 | $11,374 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 125 | $20,625 | $11,013 | 53.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 59 | $13,334 | $7,591 | 56.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 71 | 73 | $16,060 | $7,005 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $12,240 | $5,780 | 47.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $6,930 | $3,534 | 51.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 52 | $7,436 | $2,605 | 35.0% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 34 | 162 | $12,960 | $1,732 | 13.4% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 25 | 42,700 | $27,328 | $1,571 | 5.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 46 | 85 | $4,250 | $1,278 | 30.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 15 | 28 | $2,380 | $590.24 | 24.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 30 | $1,800 | $336.86 | 18.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 20 | 244 | $4,636 | $97.84 | 2.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 16 | $240.00 | $13.04 | 5.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 452 | 2,543 | $305,160 | $136,549 | 44.7% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2022 | 18 | 1,600 | $232,000 | $88,937 | 38.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 238 | 782 | $136,850 | $60,534 | 44.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 320 | 361 | $116,318 | $51,300 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 176 | $29,040 | $16,313 | 56.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 100 | 182 | $25,480 | $9,071 | 35.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 63 | 63 | $16,065 | $7,212 | 44.9% |
About Dr. Maha Assi, MD
Dr. Maha Assi, MD is a Infectious Disease healthcare provider based in Wichita, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922071224.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maha Assi, MD has received a total of $189,919 in payments from pharmaceutical and medical device companies, with $541.51 received in 2024. These payments were reported across 358 transactions from 31 companies. The most common payment nature is "" ($170,014).
As a Medicare-enrolled provider, Assi has provided services to 7,777 Medicare beneficiaries, totaling 235,503 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Wichita, KS
- Active Since 02/08/2006
- Last Updated 08/03/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1922071224
Products in Payments
- Bivigam (Drug) $170,014
- TEFLARO (Drug) $5,419
- AVYCAZ (Drug) $3,698
- REBYOTA (Biological) $2,390
- VABOMERE (Drug) $2,157
- ORBACTIV (Drug) $1,901
- FLUZONE HIGH-DOSE (Drug) $1,169
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $477.47
- Arikayce (Drug) $380.91
- DALVANCE (Drug) $329.27
- LifeVest (Device) $144.50
- DIFICID (Drug) $124.79
- ACTHAR (Biological) $122.92
- PARADISE RENAL DENERVATION SYSTEM (Device) $110.27
- TAVNEOS (Drug) $108.38
- Veltassa (Drug) $100.93
- ZERBAXA (Drug) $88.24
- NO PRODUCT DISCUSSED (Drug) $79.30
- EVUSHELD (Drug) $74.06
- GENERAL THERAPIES (Device) $60.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Wichita
Dr. Thomas Moore, Md, MD
Infectious Disease — Payments: $35,878
Infectious Disease $35,878
Dr. Margaret Hagan, Md, MD
Infectious Disease — Payments: $4,087
Infectious Disease $4,087
Dr. Keck Hartman, Md, MD
Infectious Disease — Payments: $2,429
Infectious Disease $2,429
Dr. Jerry Peterie, Md, MD
Infectious Disease — Payments: $2,180
Infectious Disease $2,180
Garret Seiler, D.o, D.O
Infectious Disease — Payments: $1,864
Infectious Disease $1,864
Dr. Shelley Jones, M.d, M.D
Infectious Disease — Payments: $1,718
Infectious Disease $1,718